The global bronchodilators market size was valued at $27,580.00 million in 2018 and is expected to reach $41,487.53 million by 2026, registering a CAGR of 5.2% from 2019 to 2026. Bronchodilators are the drugs that relax muscles that tighten around the airways. Bronchodilators open the airway and lets more air move in and out of the lungs. Bronchodilators are also used to reduce mucus from the lungs. Patients suffering from respiratory disorders consume these drugs through the help of nebulizers or inhalers. In addition, inhalation bronchodilators also have effects on mucociliary clearance. Bronchodilators are used in the treatment of obstructive lung diseases by relaxing the lungs muscles and widening the airways (bronchi). They are used in the treatment of asthma and chronic obstructive pulmonary diseases (COPD).
Surge in prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), across the globe is the major factor driving the bronchodilators market growth. In addition, rise in disposable income, geriatric population, and increase in awareness of healthcare among population are anticipated to boost the market growth. Further, increased usage of bronchodilators for the treatment of cystic fibrosis fuels the market growth. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of the bronchodilators are anticipated to hamper the market growth. On the contrary, ongoing R&D activities related to bronchodilators are anticipated to present new opportunities for the bronchodilators market.
Global Bronchodilators Market Segmentation
The bronchodilators market is segmented on the basis of indication, drugs type, route of administration, and region. Based on indication the market is categorized into asthma, chronic obstructive pulmonary disease (COPD) and others. By drugs type, it is classified into sympathomimetics, anticholinergics, phosphodiesterase inhibitor, and combination drugs. On the basis of route of administration, the market is categorized into oral, injection and inhaler. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Indication
Others segment is projected as one of the most lucrative segment.
Indication Segment Review
By indication, the asthma segment accounted for the majority of market share in 2018 and is expected to exhibit a prominent growth rate in the near future. This is attributed to the significant surge in the prevalence of asthma across the globe. For instance, according to Asthma and Allergy Foundation of America, asthma accounts for 9.8 million hospital visits, 188,968 discharges from hospital inpatient care and 1.8 million emergency department visits each year. The COPD segment is expected to show lucrative growth owing to significant surge in adoption of smoking along with exposure to certain gases or fumes in workplaces, exposure to heavy amounts of secondhand smoke, pollution, and frequent use of cooking fire without proper ventilation are responsible for COPD.
By Drug Type
Anticholinergics segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Drug Type Segment Review
By drug type, the anticholinergics segment dominated the bronchodilators market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the fact that anticholinergics are available in both long acting and short acting forms. In addition, anticholinergic bronchodilators block the parasympathetic nerve reflexes that constrict the airways and enable the air passages to remain open. Anticholinergic bronchodilators are widely being used to treat chronic obstructive pulmonary disease. The combination drug segment is anticipated to grow at the fastest CAGR in the forecast period. This growth is attributed to their properties of dilating air passages and making air flow easier. Combination drugs are most commonly a bronchodilator and a steroid.
By Region
North America segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Region Segment Review
North America held the largest share in the bronchodilators market in 2018, followed by Europe. In addition, significant increase in cystic fibrosis and increase in government initiates towards increasing awareness regrading COPD, asthma and other chronic respiratory disorders. Furthermore, presence of leading players of the bronchodilators market such as AstraZeneca, Teva Pharmaceutical Industries Ltd., among others contributes to the market growth.
However, Asia-Pacific is anticipated to grow at the highest rate during the analysis period. This is attributed to increase in respiratory disorder patient pool in Asia-Pacific, and significant improvement in the healthcare sector in this region. Moreover, improving healthcare infrastructure, increase in availability of these drugs in the market and rise in smoking habits in this region is anticipated to contribute to the market growth. In Europe, key players are adopting partnership as their key developmental strategy to introduce new bronchodilators and such partnerships are expected to give an edge to these companies over others. Moreover, factors that promote the growth of the bronchodilators market in Europe include rise in demand for bronchodilators in the pharmaceutical sector and increase in investment by the European Union for R&D in the healthcare sector.
Comprehensive competitive analysis and profiles of major market players such as, Boehringer Ingelheim, GlaxoSmithKline, F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vectura Group plc and Abbott Laboratories are provided in this report.
Key Benefits for Stakeholders:
- The bronchodilators market share and analysis is based on a comprehensive analysis of key developments in the bronchodilators industry.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global bronchodilators market.
- The study provides an in-depth analysis of the market trends to elucidate the imminent investment pockets.
- The global bronchodilators market trends are studied from 2018 to 2026.
- Information about key drivers, restrains, and opportunities and their impact analysis on the market size is provided.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
- The quantitative global bronchodilators market analysis from 2019 to 2026 is provided to determine the market potential.
Bronchodilators Market Report Highlights
| Aspects | Details |
 By Indication |
|
 By Drug Type |
|
 By Route Of Administration |
|
 By Region |
|
 Key Market Players | AstraZeneca plc., Vectura Group Plc., SANOFI, Pfizer Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Novartis AG., GlaxoSmithKline Plc. |
Analyst Review
Bronchodilators are used to lighten or loosen the mucus formed in lungs of patients suffering from respiratory disorders such as asthma and COPD. These devices enable patients to breathe properly and relieve chest pain by lung expansion and clearing excessive mucus formation. Further, increased usage of bronchodilators for treatment of chronic respiratory disorders is expected to boost the market growth. In addition, availability of various types of bronchodilators, such as short acting and long acting, is anticipated to boost the market growth in the future.
The bronchodilators market is anticipated to witness a steady growth in the future, owing to its increased use in patients suffering from bronchiectasis. However, high cost of these systems and stringent reimbursement scenario is expected to hamper the market growth in the future. Moreover, North America dominated the market in 2018, owing to surge in prevalence of respiratory disorders and awareness among patients toward the availability of these drugs. Asia-Pacific is anticipated to grow at the fastest growth rate in the future, owing to significant surge in the prevalence of COPD and asthma.
The total market value of Bronchodilators Market is $27,580.3 million in 2018.
The forecast period for Bronchodilators Market is 2019 to 2026
The market value of Bronchodilators Market in 2019 is $29,118.6 million
The base year is 2018 in Bronchodilators Market
Top companies such as, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., held a high market position in 2018.
Anticholinergics segment is the most influencing segment growing in the Bronchodilators Market
The key trend in the Bronchodilators Market is increase in incidence of asthma and COPD across the globe which drives the growth of the market.
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China and India with a CAGR of 7.3% and 8.4% respectively.
Loading Table Of Content...
